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Abstract 
Objectives: 1. List components of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain, 2. Describe the prescribing habits of 
medical residents and attending physicians within a family medicine residency program, 3. Discuss the direction of future research 
Methods: A report was generated for all patients with opioids listed as a medication at Christ Health Center family medicine clinic from 
July 2016 to June 2017. A total of 153 patients were identified with prescriptions written for chronic non-cancer pain indications. Clinical 
management via a retrospective chart review was completed utilizing a standardized data collection form centered around four of 
twelve recommendations within the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain: (1) Avoid concurrent opioid and 
benzodiazepine prescribing; (2) evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy; (3) perform 
urine drug testing before starting opioids and consider at least annually; and (4) offer/prescribe medication for opioid use disorder for 
all patients taking chronic opioids. 
Results: A total of 153 prescriptions were written for chronic indications. The most common indications were chronic back pain (32.0%), 
unspecified chronic pain (31.4%), and osteoarthritis (9.8%). Average duration of therapy was 26.6 months. Forty-two (27.5%) patients 
were concurrently receiving benzodiazepine therapy. Eighteen (11.8%) patients performed a drug test before or during therapy. 
Twenty-two (14.4%) patients had documented discussion with their prescriber evaluating the benefits and harms of their opioid 
regimens. No patients were prescribed medication for opioid overdose.  
Conclusion: Prescribing habits did not align with the four-guideline recommendations evaluated. The need for provider-focused 
education on current pain management practice guidelines was identified.  
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Introduction 
Managing non-cancer pain has become an increasingly large 
challenge for healthcare providers. In 2012, prescribers wrote 
82.5 opioid prescriptions per 100 persons in the United States.1 
As the number of opioid prescriptions has increased, so have 
the number of opioid related overdoses, resulting in opioid-
related deaths being five times higher today than they were 15 
years ago.1,2,3 From the state perspective, in 2012 Alabama 
wrote more opioid prescriptions than any other state in the 
country: 121 opioid prescriptions for every 100 people.4 
 
Despite early efforts by opioid manufacturers to convince 
prescribers that opioids were safe to use in the majority of 
patient populations, it is now understood that opioid 
dependence has a high prevalence, with roughly 25% of 
patients misusing their prescribed opioids and 10% of patients 
developing an opioid use disorder.2,5 Costs associated with 
emergent treatment of opioid overdose have been on par with 
treatment costs of other major chronic disease states such as 
asthma and HIV.6 
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Improper prescribing is a main culprit surrounding the opioid 
epidemic.1 In a 2016 letter from U.S. Surgeon General Dr. Vivek 
Murthy, more than 2 million prescribers were called upon to 
address the issues surrounding opioid prescribing in their 
practices.7 Issues in prescribing include overlapping pain 
relievers, use of opioids concurrently with benzodiazepines, use 
of long-acting pain relievers in patients with acute pain, and 
prescribing higher doses than necessary.1 Volatility of pain 
varying from patient to patient makes managing pain control 
difficult, with patients with high volatility often having poor 
outcomes in pain management.8 
 
As healthcare providers wrestle with providing adequate pain 
control while avoiding adverse effects, there has been more 
attention on this epidemic. As new guidelines and 
recommendations are published, it is important for prescribers 
to stay up to date and remain properly trained. One previous 
study compared opioid prescribing habits based on the number 
of CME hours obtained related to opioids. Prescribers with 
more CME hours related to opioid prescribing adhered to the 
guidelines more than those prescribers with less CME hours, 
illustrating the need for proper prescriber training and periodic 
updates as new guidelines and recommendations are 
published.9 In 2016, the Centers for Disease Control and 
Prevention (CDC) published a guideline for prescribing opioids 
for chronic pain (Table 1).10 This study aims to identify current 
Student Project PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                        2019, Vol. 10, No. 2, Article 10                       INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i2.1149 
2 
 
opioid prescribing habits for non-cancer pain in a family 
medicine residency program, and to evaluate if those habits 
align with specific recommendations within the 2016 CDC 
guideline. 
 
Methods 
This project was approved by the Institutional Review Board at 
Samford University in Birmingham, Alabama. Patients who 
were prescribed opioids at Christ Health Center, a family 
medicine residency program, were identified as the study 
population. A report was generated for all patients with 
documentation of an opioid as an active or inactive medication 
on the medication list between July 1, 2016 and June 30, 2017. 
Patients were included in the analysis if they were 18 years or 
older and were prescribed an opioid for a chronic indication. 
Patients were excluded if they were receiving their opioid 
prescription from an outside provider or were prescribed 
opioids for cancer-related pain. A chart review was conducted 
analyzing the following recommendations from the 2016 CDC 
Guideline for Prescribing Opioids for Chronic Pain: (1) avoid 
opioids in patients concurrently receiving benzodiazepine 
therapy; (2) perform a urine drug test on patients before opioid 
therapy and at least annually; (3) evaluate patients for benefits 
and harms of opioid therapy; and (4) consider a prescription for 
an opioid overdose medication. Results were completed using 
a standardized data collected form. Data were collected 
regarding the indication of the opioid, the duration of therapy, 
concomitant use of benzodiazepines, documentation of drug 
screening at any point in therapy, documentation of risks versus 
benefits for continuation of therapy, and need for an opioid 
overdose medication. No patients included in the study 
received more than one course of therapy. Because medical 
residents work under direct supervision of an attending 
physician when prescribing opioids, data were not divided 
between the two cohorts. Therefore, the term “prescriber” 
refers to both medical residents and attending physicians.   
 
Results 
After running a data report, 623 patient charts were identified 
as having documentation of an opioid on their medication list 
between July 1, 2016 and June 30, 2017. Of those identified, 
153 received their prescription from a provider within the clinic 
for a chronic non-cancer pain indication. The average age was 
61.3 years, with 71% of patients being female. The most 
common indication for opioid use was chronic back pain 
(32.0%), followed by unspecified chronic pain (31.4%) and 
osteoarthritis (9.8%). A full list of indications can be found in 
Figure 1. Average duration of opioid therapy was 26.6 months.  
 
Various aspects of care were compared to the CDC guideline for 
chronic pain. Forty-two (27.5%) patients were concurrently 
receiving benzodiazepine therapy. Eighteen (11.8%) patients 
performed a urine drug test during therapy to assess for 
prescribed medications and illicit substance use. Twenty-two 
(14.4%) patients had documented discussion with their 
prescriber evaluating the benefits and harms of their opioid 
regimens. No patients were prescribed medication for opioid 
overdose.  
 
Discussion 
This retrospective chart review examined opioid prescribing 
habits in a family medicine residency program. Overall, 
prescribers in the clinic did not closely follow the 
recommendations provided by the CDC guideline. Almost half 
of patients concurrently on a benzodiazepine were prescribed 
an opioid, only 12% received a urine drug test before or during 
opioid treatment, 14% were appropriately evaluated for 
benefits & harms, and zero patients received a prescription for 
opioid overdose medication. Prescribers had been previously 
educated on the 2016 CDC guidelines, but our findings indicate 
that more education on the guidelines is warranted. In the clinic 
specifically, several patients have been receiving chronic opioid 
therapy for years, challenging prescribers to have difficult 
conversations with patients about their potential adjustments 
to treatment plans. Addressing those differences in 
expectations is a critical obstacle all prescribers endure, and 
educating them on how to have those discussions could be a 
vital resource to achieve the ultimate goal of creating a space 
where providers and patients are able to speak freely and 
develop a plan that best promotes patient wellness.11 Providers 
must also seek to develop better understanding of their own 
perceptions of pain management, as various biases exist that 
can create disparities in providing appropriate care for patients 
with chronic pain.12 
 
One limitation of this study is that only the 2016 CDC Guideline 
for Prescribing Opioids for Chronic Pain was used to evaluate 
practices. The American Academy of Pain Medicine and the 
American Society of Anesthesiologists also provide guidelines 
into pain management, but they were not utilized.12,13 While 
these guidelines share many commonalities, certain differences 
exist, such as the use of benzodiazepines. Having evaluated only 
four of twelve specific recommendations within the CDC 
guideline, results could be strengthened with a future study 
evaluating the remaining eight recommendations. Very few 
electronic health records had documented evidence of 
discussing benefits and harms of opioid therapy with patients 
during the visit. However, prescribers could have had these 
conversations with patients but did not document the 
conversation, as research has indicated that underreporting 
and miscommunication of what should be documented in the 
EHR are major sources of discrepancy.14 Lastly, our small 
sample size of 153 and prescribers within the setting of one 
residency program limit its ability to be extrapolated to the 
larger population.  
 
This chart review demonstrated that areas of improvement for 
medical residents and attending physicians exist in regard to 
evaluating benefits and risks of continuing opioid therapy, as 
well as providing treatment for possible overdose. Education 
opportunities need to be provided to not only understand 
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guideline recommendations, but also the importance of 
discussing pain management expectations and treatment plans 
with patients. 
 
Conclusion 
Of the specific recommendations evaluated, prescribing habits 
did not align with the 2016 CDC Guideline for Prescribing 
Opioids for Chronic Pain. The need for provider-focused 
education on guidelines as well as management of patient 
expectations was identified. Prescribers would benefit from 
focused training in concurrent use of opioids and 
benzodiazepines, the appropriateness of prescribing a 
medication for opioid overdose, and the utility of discussing 
expectations with patients while evaluating benefits and harms 
of their treatment regimens. 
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Appendix 
Table 1. Recommendations from the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain 
Determining When to Initiate or Continue Opioids for Chronic Pain 
Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid 
therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, 
they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate. 
(Recommendation category: A, Evidence type: 3) 
Before starting opioid therapy, clinicians should establish treatment goals with all patients, including realistic goals for pain and 
function, and should consider how opioid therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue 
opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety. 
(Recommendation category: A, Evidence type: 4) 
Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of 
opioid therapy and patient and clinician responsibilities for managing therapy. (Recommendation category: A, Evidence type: 3) 
Opioid Selection, Dosage, Duration, Follow-Up, and Discontinuation  
When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-
release/long-acting (ER/LA) opioids. (Recommendation category: A, Evidence type: 4) 
 
When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use caution when prescribing 
opioids at any dosage, should carefully reassess evidence of individual benefits and risks when considering increasing dosage 
to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a 
decision to titrate dosage to ≥90 MME/day. (Recommendation category: A, Evidence type: 3) 
Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe 
the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected 
duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be 
needed. (Recommendation category: A, Evidence type: 4) 
Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of 
dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more 
frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work 
with patients to taper opioids to lower dosages or to taper and discontinue opioids.* (Recommendation category: A, Evidence 
type: 4) 
Assessing Risk and Addressing Harms 
Clinicians should review the patient’s history of controlled substance prescriptions using state prescription drug monitoring 
program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or 
her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically 
during opioid therapy for chronic pain, ranging from every prescription to every 3 months. (Recommendation category: A, 
Evidence type: 4) 
When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider 
urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit 
drugs.* (Recommendation category: B, Evidence type: 4) 
Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible.* 
(Recommendation category: A, Evidence type: 3) 
Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or 
methadone in combination with behavioral therapies) for patients with opioid use disorder.* (Recommendation category: A, 
Evidence type: 2) 
* Recommendation evaluated in this study 
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